ArticleiScience2024
Risk factors and prescription patterns analysis for macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Mycoplasma pneumoniae infection impairs asthma control in pediatric patients and exacerbates allergic airway inflammation.Respiratory research · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Article
- AgeFrontiers in pediatrics · 2026Article
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Clinical score for early escalation in pediatric A2063G Mycoplasma pneumoniae pneumonia: a retrospective cohort study.BMC infectious diseases · 2025Article
- Analysis of the characteristics of mixed infections with Mycoplasma pneumoniae in children.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-line macrolide therapy is encountering challenges due to the escalating incidence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP). This study aimed to illustrate prescription patterns among children diagnosed with either macrolide-sensitive Mycoplasma pneumoniae pneumonia (MSMPP) or MRMPP and to further analyze the risk factors associated with MRMPP. This research encompassed 825 children who were diagnosed with Mycoplasma pneumoniae pneumonia (MPP) at a tertiary hospital located in central China in 2023. Notably, the MRMPP group had a longer fever duration compared to the MSMPP group. A combination of doxycycline and piperacillin-tazobactam was the most frequently used treatment for hospitalized MRMPP children, whereas azithromycin was the primary choice for the MSMPP group. More children in the MRMPP group required discharge medications, primarily doxycycline, whereas the MSMPP group primarily received azithromycin. Furthermore, a history of allergy emerged as an increased risk factor for MRMPP, alongside age, fever, pulmonary imaging changes, and co-detections of bacteria or fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.